Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News May 11 2022 | 2021 Annual Scientific Meeting OnDemand Content Available in HFSA Learning Center HFSA News Annual Scientific Meeting HFSA Learning Center Professional Development Provider Education Read More May 10 2022 | From Patient to Agent Practice News Journal of Cardiac Failure Patient Story Press Release Read More May 10 2022 | Heart Failure Awareness 365: Basics of Heart Failure Part II - Heart Failure Treatment Best Practices Patient News Heart Failure Awareness 365 Patient Resource Read More May 6 2022 | FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction Industry News Industry Read More Apr 28 2022 | U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms Industry News In The News Industry Read More Pagination First page « First Previous page ‹ Previous … Page 64 Page 65 Page 66 Page 67 Current page 68 Page 69 Page 70 Page 71 Page 72 … Next page Next › Last page Last »
May 11 2022 | 2021 Annual Scientific Meeting OnDemand Content Available in HFSA Learning Center HFSA News Annual Scientific Meeting HFSA Learning Center Professional Development Provider Education Read More
May 10 2022 | From Patient to Agent Practice News Journal of Cardiac Failure Patient Story Press Release Read More
May 10 2022 | Heart Failure Awareness 365: Basics of Heart Failure Part II - Heart Failure Treatment Best Practices Patient News Heart Failure Awareness 365 Patient Resource Read More
May 6 2022 | FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction Industry News Industry Read More
Apr 28 2022 | U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms Industry News In The News Industry Read More
